MOR106 was jointly discovered by MorphoSys and Galapagos under their collaboration, and has a novel mode of action with potential application in inflammation. The primary objective of the
The IND is now active. This will be Adaptimmune’s second wholly-owned therapeutic candidate to enter clinical trials. The company initiated a study in December 2015 to evaluate its
The CHMP also noted that the importance of favourable effects of RUCONEST is further supported by the continued availability of supply of RUCONEST (produced by recombinant technology) in
The randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, phyarmacodynamics, and glucose and insulin dose-lowering properties of REMD-477 in up to 20 patients with type 1 diabetes
These agreements relate to Eisai’s global oncology therapies, Halaven (eribulin) and Lenvima (lenvatinib), as well as the Company’s global epilepsy therapy, Fycompa (perampanel). Under the proposed agreements, important
Additionally, Incyte has amended its Collaboration and License Agreement with Novartis, granting Novartis exclusive research, development and commercialization rights for ruxolitinib in GVHD outside the U.S. "We are
Lumos will use the proceeds for clinical trials and commercialization of its lead compound, LUM-001, for the treatment of Creatine Transporter Deficiency (CTD). Funding will also be used
Under the CRADA, NantBioScience and its affiliates, such as NantKwest, will work together to further develop their proprietary recombinant NK and monoclonal antibodies in monotherapy and in combination
Based on these data, Ironwood intends to discontinue development of IW-9179 for gastroparesis. "Our mission is to bring innovative medicines to patients in need, and exploratory trials are
Trailing twelve-month sales for the product are $7.5 million according to IMS Health. ANI president and CEO Arthur S. Przybyl said: "When launched, this will be our third
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.